Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (336 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: baselineother protocolmay applycriteria mayunstable
  Phrases that lowered it: topicalallergicadministrationthe studyprick
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 62 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: not given (lowers risk) · Who can join
• Sponsor's past termination rate: 7.8% (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 84.7% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 10.9% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 307 (lowers risk) · Sponsor's track record
• Minimum age: 10 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis NCT01258309 · started 2010 · scored riskier than 8% of active trials completed
• An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis NCT01037179 · started 2010 · scored riskier than 25% of active trials completed
• A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle NCT03489941 · started 2018 · scored riskier than 11% of active trials completed
• Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis NCT01860664 · started 2013 · scored riskier than 18% of active trials terminated
• Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC) NCT01435460 · started 2010 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.